Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibandronate vs denosumab after romosozumab in primary osteoporosis
jRCT1041190094Not yet recruiting
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of ibandronate and denosumab in involutional osteoporosis (3 arms). Primary endpoint: Change in bone mineral density at lumbar spine and total hip at 12 months. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
ibandronatedenosumab
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on jRCT1041190094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041190094.